Synpromics continues to expand its business through its ability to attract significant investment and key strategic alliances, to develop next-generation products based on its synthetic promoter technology.
Corporate

2010

Synpromics was founded to commercialise proprietary and patent-pending technology, developed by Dr Michael Roberts, in the emerging field of synthetic biology.

Corporate

2011

Company establishes laboratories at Edinburgh BioQuarter

Technology

2011

The company completes its proof-of-concept by generating cancer-specific promoters and files its first patent application at the European Patent Office.

Corporate

2012

Synpromics raised its first seed capital.

Corporate

2012

Research collaboration deal with Dow Agroscience (DAS) for agricultural applications and a partnership deal with Avanticell Sciences to incorporate synthetic promoters in food testing products.

Corporate

2013

The company attracted investment from the Scottish Investment Bank.

Technology

2013

Protoplast screening method developed and IP filed. Screening of maize library begins.

Corporate

2013

Synpromics secured its position as one of the UK's leading Synthetic Biology enterprises, establishing itself as a founding member of the Bioindustry Association's (BIA) synthetic biology group.

Technology

2013

Human lung cell promoter library constructed, designed to inducibly express genes in response to TNF-alpha.

Corporate

2013

Awarded a prestigious grant by the UK government through the Technology Strategy Board (TSB) to produce synthetic promoters to enhance biopharmaceutical manufacturing processes.

Technology

2013

Maize promoter library designed and constructed.

Corporate

2014

The company builds on its success with the TSB and leverages funding from two different competitions to initiate projects with Touchlight Genetics to create promoters for DNA vaccines development and with Ingenza and Synthace to generate synthetic promoters for application in yeast-based systems.

Technology

2014

CHO specific promoter libraries created, with a view to increase bio-process yields.

Corporate

2014

New Board appointed with Dr John Brown as Chairman, and Dr David Venables as CEO.

Technology

2014

Human cell specific promoter libraries created for liver cell, keratinocytes, and dendritic cells.

Corporate

2015

Completes a £2.1M investment from Calculus Capital.

Technology

2015

Yeast specific promoter libraries created and screened; promoters are constitutive and inducible under a variety of culture conditions.

Corporate

2015

Signed research and collaboration agreements in Cell & Gene Therapy with uniQure, AGTC and Avalanche.

Technology

2015

CHO specific promoters isolated displaying up to 10-fold higher activity than industry standard promoters.

Technology

2015

Highly specific and active promoters identified for liver cells, keratinocytes and dendritics cells

Corporate

2015

Signed first CHO promoter research agreement with large Pharma.